- Citations, last 5 years
- 19
- Works, last 5 years
- 4
- h-index
- 13
- Scientists listed
- 2
- Grants since 2016
- 19
Grants received
2025–2027 · research · R44
Treatment of GM1 gangliosidosis CNS manifestations by AAV systemic expression of lectin-enhanced enzyme
Walter Acosta · BioStrategies (United States) · funded by National Institutes of Health
2023–2025 · research · R43
Morquio A therapy integrating gene transfer with lectin-enhanced enzyme delivery to treat multisystemic clinical impairments of rare metabolic childhood diseases
Walter Acosta · BioStrategies (United States) · funded by National Institutes of Health
2023–2025 · research · R44
Gene Therapy that Systemically Produces Brain-penetrating Replacement Enzyme for MPS IIIA (Sanfilippo A Syndrome)
Carole L. Cramer · BioStrategies (United States) · funded by National Institutes of Health
2023–2025 · research · R44
Gene Therapy that Systemically Produces Brain-penetrating Replacement Enzyme for MPS IIIA (Sanfilippo A Syndrome)
Carole L. Cramer · BioStrategies (United States) · funded by National Institutes of Health
2022–2024 · contract · N02
NINDS, NIH BPN, NIH HEAL AND OTHER NIH NEUROSCIENCE-FOCUSED DRUG DISCOVERY AND DEVELOPMENT PROGRAMS WITH TOXICOLOGY CONSULTING SERVICES
Marcie Wood · BioStrategies (United States) · funded by National Institutes of Health
2022–2024 · contract · N02
NINDS TOXICOLOGY CONSULTING SERVICES (NIH BPN, NIH HEAL AND OTHER NIH NEUROSCIENCE-FOCUSED DRUG DISCOVERY AND DEVELOPMENT PROGRAMS)
Marcie Wood · BioStrategies (United States) · funded by National Institutes of Health
2022–2024 · contract · N02
NINDS TOXICOLOGY CONSULTING SERVICES (NIH BPN, NIH HEAL AND OTHER NIH NEUROSCIENCE-FOCUSED DRUG DISCOVERY AND DEVELOPMENT PROGRAMS)
Marcie Wood · BioStrategies (United States) · funded by National Institutes of Health
2022–2023 · contract · N02
NINDS, NIH BPN, NIH HEAL AND OTHER NIH NEUROSCIENCE-FOCUSED DRUG DISCOVERY AND DEVELOPMENT PROGRAMS WITH TOXICOLOGY CONSULTING SERVICES
Marcie Wood · BioStrategies (United States) · funded by National Institutes of Health
2022–2024 · contract · N02
NINDS, NIH BPN, NIH HEAL AND OTHER NIH NEUROSCIENCE-FOCUSED DRUG DISCOVERY AND DEVELOPMENT PROGRAMS WITH TOXICOLOGY CONSULTING SERVICES
Marcie Wood · BioStrategies (United States) · funded by National Institutes of Health
2022–2024 · research · R43
Krabbe disease therapy integrating gene transfer with lectin-enhanced enzyme delivery to treat pathologies of the CNS
Walter Acosta · BioStrategies (United States) · funded by National Institutes of Health
2020–2022 · research · R43
Treatment of muscular symptoms in Pompe rare disease via lectin assisted ERT delivery
Carole L. Cramer · BioStrategies (United States) · funded by National Institutes of Health
2019–2021 · research · R43
Lectin-mediated ERT Delivered to Cardiac Tissue in Fabry Disease
Walter Acosta · BioStrategies (United States) · funded by National Institutes of Health
2018–2021 · research · R43
MPS I Skeletal Disease Therapy with Novel Lectin-delivered Replacement Enzyme
Walter Acosta · BioStrategies (United States) · funded by National Institutes of Health
2017–2022 · research · R44
Improving MPS I ERT Efficacy through Lectin-Mediated Delivery
Walter Acosta · BioStrategies (United States) · funded by National Institutes of Health
2017–2019 · research · R44
Improving MPS I ERT Efficacy through Lectin-Mediated Delivery
Walter Acosta · BioStrategies (United States) · funded by National Institutes of Health
2016–2018 · research · R43
Enzyme Replacement Therapeutics for Rare Childhood Genetic Diseases: An ERT Delivery System that Mitigates Immune-sensitization
Walter Acosta · BioStrategies (United States) · funded by National Institutes of Health
2016–2022 · research · R44
Enzyme Replacement Therapeutics for Rare Childhood Genetic Diseases: An ERT Delivery System that Mitigates Immune-sensitization
Walter Acosta · BioStrategies (United States) · funded by National Institutes of Health
2016–2024 · research · R44
Enzyme Replacement Therapeutics for Rare Childhood Genetic Diseases: An ERT Delivery System that Mitigates Immune-sensitization
Walter Acosta · BioStrategies (United States) · funded by National Institutes of Health
2014–2022 · research · R44
Enzyme replacement therapy for GM1 gangliosidosis lysosomal rare disease
Walter Acosta · BioStrategies (United States) · funded by National Institutes of Health
